7 5 GA “duet”: Dual inhibition of validated complement pathways along with the inflammasome pathway (NLRP3) GA “Duet” B i o p o l y m e r w i t h o n e m a c r o c y c l e p e p t i d e a n d o n e s m a l l m o l e c u l e Peptide Inhibitor of Complement Anti-C3 and anti-C5 have been validated for GA, but current therapies do not sufficiently halt disease progression and are limited by frequent injections NLRP3 Inhibitor Small Molecule Prevents inflammasome activation that contributes to AMD pathology ABCD Platform for Extended Durability High molecular weight to increase ocular half-life, providing potential for a quarterly dosed intravitreal therapy Administered via intravitreal injection Dual inhibition of inflammatory and complement pathways may better address the multifactorial biology driving GA progression